Cargando…
Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos
Angiogenesis is a fundamental developmental process and a hallmark of cancer progression. Receptor tyrosine kinases (RTK) are targets for cancer therapy which may include their action as anti-angiogenic agents. Derazantinib (DZB) is an inhibitor of the fibroblast growth factor receptors (FGFRs) 1–3...
Autores principales: | Kotini, Maria P., Bachmann, Felix, Spickermann, Jochen, McSheehy, Paul M., Affolter, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824571/ https://www.ncbi.nlm.nih.gov/pubmed/33396726 http://dx.doi.org/10.3390/ph14010025 |
Ejemplares similares
-
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
por: Mazzaferro, Vincenzo, et al.
Publicado: (2018) -
Lack of pharmacokinetic interaction between derazantinib and naringin in rats
por: Liu, Ya-nan, et al.
Publicado: (2023) -
Vinculin strengthens the endothelial barrier during vascular development
por: van der Stoel, Miesje M, et al.
Publicado: (2022) -
Blood Flow Changes Coincide with Cellular Rearrangements during Blood Vessel Pruning in Zebrafish Embryos
por: Kochhan, Eva, et al.
Publicado: (2013) -
Correction: Blood Flow Changes Coincide with Cellular Rearrangements during Blood Vessel Pruning in Zebrafish Embryos
por: Kochhan, Eva, et al.
Publicado: (2014)